openPR Logo
Press release

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market: Rise in STDs Makes Asia Pacific Key Region

11-22-2017 08:33 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Some of the prominent names in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market are Valeant Pharmaceuticals, Roche AG, Perrigo Company plc, Fougera Pharmaceuticals, Clinigen Group plc., and Fresenius Kabi USA. Of them, Valeant Pharmaceuticals accounts for a leading share in the HPV therapeutics market and Roche AG accounts for a dominant share in the CMV therapeutics market.

Read Report Overview @ https://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html

A report by Transparency Market Research forecasts the global human papillomavirus (HPV) therapeutics market to rise at a CAGR of 7.7% during the period between 2014 and 2020 to become worth US$2.34 bn by 2020 from US$1.40 bn in 2012. According to the report, the global cytomegalovirus (CMV) market will rise at a 1.49 % CAGR from 2014 to 2020 to attain a value of US$922.8 mn by 2020 from US$870.1 mn in 2012.

Depending upon the types of drugs, the global human papillomavirus (HPV) therapeutics market can be segmented into the following drug classes – anti-neoplastic agents, immunomodulators, sinecatechins, and keratolytic agents. Among them, the immunomodulators leads the market with maximum share. In terms of growth rate, however, the sinecatechins segment will surpass all.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986

The cytomegalovirus (CMV) therapeutics market, again, can be divided on the basis of antiviral drugs into foscarnet, ganciclovir/valganciclovir (first line drugs), and cidofovir. Of them, ganciclovir and valganciclovir together contribute a lion’s share in the revenue in the overall CMV therapeutics market.

Geographically, the key segments of the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market are North America, South America, Europe, Asia Pacific, and the Rest of the World. At present, South America and Asia Pacific are considered the most lucrative markets on account of the fast developing healthcare infrastructure, increasing affluence of the people, cultural shifts, and a booming tourism industry leading to high instances of STDs.

The alarming rise of human papillomavirus (HPV) in people of both developed and developing nations has been the primary growth driver of the HPV therapeutics market. The lead analyst of the TMR report elaborates, “Over a 100 strains of human papillomavirus (HPV) have been identified so far. Of them, certain types are known to cause warts or papillomas that progress to malignant or benign cancers.

Request Human Papillomavirus and Cytomegalovirus Therapeutics Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3986

HPV infections are common in adolescents and younget adults and is known to affect adolescent females the most. According to Centre for Disease Control (CDC), about 20 million persons were infected in 2012 in the U.S., and an estimated 6.2 million new HPV infections were occurring every year. All these have majorly fuelled the global HPV therapeutics market.”

The cytomegalovirus (CMV) therapeutics market, on the other hand, has received a boost from the launch of brincidofovir in 2016. The launch of letermovir in 2018 will also boost the market.

Serving to deal a blow to the growth in the global human papillomavirus (HPV) market is the relatively dry pipeline of drugs and the availability of different substitute treatments such as laser therapy and cryotherapy.

Buy Full uman Papillomavirus and Cytomegalovirus Therapeutics Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=3986<ype=S

About TMR

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market: Rise in STDs Makes Asia Pacific Key Region here

News-ID: 827629 • Views: 205

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HPV

HPV Vaccines Market Insights by Size, Status and Forecast 2024
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. More than 40 types of HPV viruses are easily transferred from one person to another by sexual
Cytology and HPV Testing Market - Research Analysis
The nature of the both the markets for cytology testing and HPV or human papillomavirus testing is oligopolistic in nature, states Transparency Market Research (TMR) in a research report. With the presence of only a handful of leading companies in the market, the competition is not that high as they compete among themselves with different or almost similar strategies. These few players are currently enjoying their reign in the global
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
"The Report Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. Human papillomavirus (HPV) is the most common viral infection
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
HPV Testing Market 2017- Qiagen, Roche Diagnostics, Hologic
HPV Testing Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors. “The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The